US Food and Drug Administration‐approved agents for the treatment of obesity include appetite suppressants, such as glucagon‐like peptide‐1 receptor (GLP‐1R) agonists (liraglutide and semaglutide), noradrenergic drugs (phentermine/topiramate and naltrexone/bupropion), and pancreatic lipase inhibitors (orlistat).20, 21. Here, GLP1R is linked to obesity disorder.